Novartis AG
Use of nicotinic acetylcholine receptor alpha 7 activators

Abstract:

The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease.